Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.36 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FABP6 | P51161 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338444 | 0.84 | APEX1 (0.34) | CA1CA2PDE3AKMT2AMAPK1 | |
| SCHEMBL7938899 | 0.76 | MMP12 (0.40) | KMT2AMAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL30792604 | 0.76 | CYP3A4 (0.55) | CA1CA2KMT2ASLC5A2ALDH1A1 | |
| SCHEMBL9518303 | 0.76 | BLM (0.46) | CA2KMT2ASLC5A2TDP1CASP3 | |
| SCHEMBL1167973 | 0.76 | LMNA (0.51) | CA1CA2KMT2AMAPK1MAPKAPK2 | |
| SCHEMBL31152587 | 0.76 | AHR (0.40) | KMT2AMAP2K4SLC5A2NOTUMKDM4E | |
| SCHEMBL11694183 | 0.75 | CA1 (0.40) | CA1CA2PDE3ANOTUMKDM4E | |
| Hydrochloric Acid SCHEMBL4269947 | 0.74 | LMNA (0.50) | CA1CA2KMT2AMAPK1MAPKAPK2 | |
| SCHEMBL10845738 | 0.72 | SLC5A2 (0.46) | SLC5A2ALDH1A1RAB9AGAANPC1 | |
| SCHEMBL16211043 | 0.72 | KIF11 (0.40) | CA1CA2KMT2AALDH1A1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-10449192-B2 | Phthalazinone derivatives | KUDO PHARMACEUTICALS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9566276-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| US-20110015187-A1 | SUBSTITUTED HETEROARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | US | disclosed |
| US-20110015187-A1 | SUBSTITUTED HETEROARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | US | disclosed |
| EP-2090579-A1 | Substituted heteroarylamide diazepinopyrimidone derivatives | Sanofi-Aventis (FR) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095792-A2 | SUBSTITUTED HETEROARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | CA1 1388/4885CA2 2230/4885PDE3A 4447/4885 |
| US-10449192-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | CA1 1510/4885CA2 2202/4885PDE3A 4457/4885 |
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | CA1 1510/4885CA2 2202/4885PDE3A 4457/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | CA1 3534/4885CA2 1305/4885PDE3A 3490/4885 |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | NSUN2, UPF1, NSUN3 | CA1 4741/4885CA2 4695/4885PDE3A 911/4885 |
| US-20110015187-A1 | SUBSTITUTED HETEROARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES | WEE1, CBR1, WEE2 | CA1 2325/4885CA2 2593/4885PDE3A 1178/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | CA1 1388/4885CA2 2230/4885PDE3A 4447/4885 |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | CA1 1510/4885CA2 2202/4885PDE3A 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.